TY - JOUR
T1 - B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients
AU - de Pontes, Robéria Mendonça
AU - Flores-Montero, Juan
AU - EuroFlow Consortium
AU - Sanoja-Flores, Luzalba
AU - Puig, Noemi
AU - Pessoa de Magalhães, Roberto J.
AU - Corral-Mateos, Alba
AU - Salgado, Anna Beatriz
AU - García-Sánchez, Omar
AU - Pérez-Morán, José
AU - Mateos, Maria Victoria
AU - Burgos, Leire
AU - Paiva, Bruno
AU - Marvelde, Jeroen Te
AU - van der Velden, Vincent H.J.
AU - Aguilar, Carlos
AU - Bárez, Abelardo
AU - García-Mateo, Aranzazú
AU - Labrador, Jorge
AU - Leoz, Pilar
AU - Aguilera-Sanz, Carmen
AU - Durie, Brian
AU - van Dongen, Jacques J.M.
AU - Maiolino, Angelo
AU - da Costa, Elaine Sobral
AU - Orfao, Alberto
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/4/3
Y1 - 2021/4/3
N2 - B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (≥50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naïve B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19− nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome.
AB - B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (≥50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naïve B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19− nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome.
UR - https://www.scopus.com/pages/publications/85103486252
U2 - 10.3390/cancers13071704
DO - 10.3390/cancers13071704
M3 - Article
C2 - 33916787
AN - SCOPUS:85103486252
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 7
M1 - 1704
ER -
